What is Jounce Therapeutics, Inc. (JNCE)?

Jounce Therapeutics, Inc. (JNCE) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of JNCE?

The current price of JNCE is $1.88. Prices are updated in real time on Stocks360.

What is JNCE's price-to-earnings (PE) ratio?

JNCE's trailing twelve-month PE ratio is -1.90, based on current price and earnings per share data available on Stocks360.

What is JNCE's market capitalization?

JNCE's market capitalization is $98,954,740.00, placing it in the small-cap tier.

Jounce Therapeutics, Inc. (JNCE)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$1.88

Market Cap

$98.95M

PE (TTM)

-1.90

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.75

Day Range

$1.88 – $1.93

52-wk Range

$0.58 – $5.37

Avg Volume

N/A

Volume

11.60M

Jounce Therapeutics, Inc. (JNCE) is a publicly traded company in the Healthcare sector. Latest price: $1.88. Market cap $98.95M. Trailing PE -1.90. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

May 4, 2023

EPS $-0.72 vs est. $-0.72

Beat by $0.00

Proprietary Signals

Signal snapshot temporarily unavailable.

About Jounce Therapeutics, Inc.

Jounce Therapeutics, Inc. is an immunotherapy firm currently in the clinical development phase, dedicated to discovering and advancing new cancer treatments. A key asset in its pipeline is vopratelimab, a monoclonal antibody presently in Phase II clinical trials. This therapeutic agent functions by binding to and activating the Inducible T cell CO-Stimulator (ICOS), a specific protein located on the surface of T cells within various solid tumors. The company is also progressing JTX-8064, an antibody designed to target leukocyte immunoglobulin like receptor B2 (LILRB2), a cell surface receptor found on macrophages. Additionally, JTX-1484 is under development, focusing on myeloid targets. Completing its innovative portfolio is JTX-1811, an anti-CCR8 monoclonal antibody precisely engineered to selectively reduce the presence of intra-tumoral T regulatory cells within the tumor's microenvironment. Jounce Therapeutics, Inc. was founded in 2012 and maintains its primary operational base in Cambridge, Massachusetts.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-1.90×
P/S (TTM)	1.21×
P/B	0.53×
PEG	0.09×
P/FCF (TTM)	-3.32×
EV / EBITDA	0.83×
EV / Sales	-0.51×
Earnings Yield	-52.41%
Free Cash Flow Yield	-30.11%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$41.60M
Net Income (TTM)	-$51.86M
Free Cash Flow (TTM)	-$29.80M
Net Debt	-$140.55M
Working Capital	$173.66M
Gross Margin	100.00%
Operating Margin	-63.71%
Net Margin	-62.10%
Return on Equity	-25.03%
Return on Invested Capital	-27.05%